Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

BACKGROUND: Antibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti–PD-L1) mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaishampayan, Ulka, Schöffski, Patrick, Ravaud, Alain, Borel, Christian, Peguero, Julio, Chaves, Jorge, Morris, John C., Kotecki, Nuria, Smakal, Martin, Zhou, Dongli, Guenther, Silke, Bajars, Marcis, Gulley, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813090/
https://www.ncbi.nlm.nih.gov/pubmed/31651359
http://dx.doi.org/10.1186/s40425-019-0746-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813090/
https://www.ncbi.nlm.nih.gov/pubmed/31651359
http://dx.doi.org/10.1186/s40425-019-0746-2

Ejemplares similares